<?xml version="1.0" encoding="UTF-8"?>
<p id="P23">Overall, 31 patients were enrolled between July 2013 and November 2015 at 5 study sites. Thirty patients received â‰¥ 1 dose of CC-486 and comprised the intention-to-treat population. In the combined 7-day dosing cohorts, 3 patients received CC-486 200 mg QD (Cohort 1) and 4 received 300 mg QD (Cohort 2). In the 14-day dosing cohorts, 4 patients received CC-486 150 mg QD (Cohort 3) and 19 patients received CC-486 200 mg QD in an expansion cohort (Cohort 4).</p>
